EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study

Hong Pan, Zhen Gao, Yu Lian, Jingyu Zhao, Lele Zhang, Weiwang Li, Ruonan Li, Qian Liang, Jing Xu, Liyun Li, Xiao Yu, Zhexiang Kuang und 2 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-024-06171-3 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Hong Pan und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Azacitidine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While Azacitidine combined with HAG (HHT, low-dose cytarabine, G-CSF) regimen has shown promise in treating older and unfit patients with acute myeloid leukemia (AML), its efficacy in younger patients remains understudied. This study evaluates the effectiveness and safety of Azacitidine combined with the HAG regimen in a broader patient cohort, including newly diagnosed and relapsed/refractory AML patients. This single-center, prospective cohort included patients with acute myeloid leukemia admitted to our center from June 2019 to Oct 2022 for induction chemotherapy with the HAGA regimen (Azacitidine combined with HAG). We focused on patients' remission rate, MRD (minimal residual disease) conversion and safety. 71 patients with newly diagnosed or R/R AML were enrolled in this study, with a median follow-up time of 20.5 months. After two cycles of HAGA, patients received 3 cycles intermediate-dose Cytarabine and 1 cycle HAGA regimen as consolidation therapies. The CRc (composite complete remission) rate of HAGA regimen as induction chemotherapy for the overall cohort was 85.9% (61/71), which included 71.8% (51/71) CR and 14.1% (10/71) CRi. The CRc with MRD-negative rate was 76.1%. Median OS (overall survival) and DFS (disease free survival) were not yet reached, and the estimated 24-month OS rate was 65.4% (95%CI: 48.4-78.0%), the estimated 24-month DFS rate 66.0% (95%CI: 48.1-79.0%). Only one patient died in induction. The HAGA regimen can be a new option in addition to intense chemotherapy for newly diagnosed or R/R AML, and with high safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteCytarabineAntineoplastic Combined Chemotherapy ProtocolsAzacitidineHumansMaleFemaleMiddle AgedProspective StudiesAgedAdultGranulocyte Colony-Stimulating FactorAged, 80 and overRecurrenceYoung AdultFollow-Up Studies

Stichwörter der Autor:innen

AMLAzacitidineHAGAInduction therapyMinimal residual disease

Substanzen

CytarabineAzacitidineGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
  • Tianjin Institutes of Health Science, Tianjin, 301600, China.
  • Red Blood Cell Diseases Center & Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
  • Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China.
  • Zhoukou Center Hospital, Zhoukou, 466099, China.
  • Tianjin Institutes of Health Science, Tianjin, 301600, China. fangliwei@ihcams.ac.cn.

Förderung

  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences
  • the National Natural Science Foundation of China

Zitieren

APA

Pan, H., Gao, Z., Lian, Y., Zhao, J., Zhang, L., Li, W., Li, R., Liang, Q., Xu, J., Li, L., Yu, X., Kuang, Z., Shi, J., & Fang, L. (2025). Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study. Annals of Hematology. https://doi.org/10.1007/s00277-024-06171-3

Vancouver

Pan H, Gao Z, Lian Y, Zhao J, Zhang L, Li W, et al. Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study. Annals of Hematology. 2025. doi:10.1007/s00277-024-06171-3

BibTeX
@article{Pan2025,
  author = {Pan, Hong and Gao, Zhen and Lian, Yu and Zhao, Jingyu and Zhang, Lele and Li, Weiwang and Li, Ruonan and Liang, Qian and Xu, Jing and Li, Liyun and Yu, Xiao and Kuang, Zhexiang and Shi, Jun and Fang, Liwei},
  title = {Azacitidine in combination with HAG for newly diagnosed and relapsed/refractory AML: a prospective cohort study},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-024-06171-3}
}
Kostenlos starten →